In an international study of 682 lung cancer patients, roughly half of the participants were given the daily pill for three years, while the other half received a placebo.
Five years after their diagnosis, 88% of those who took the pill were still alive, compared with 78% of the placebo group. The study was funded by AstraZeneca and included people from more than 20 countries across the U.S., Europe, South America, Asia and the Middle East.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patientsAstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.
Source: Reuters - 🏆 2. / 97 Read more »
Lung cancer deaths cut in half with AstraZeneca pill, large trial findsA once-daily pill from drugmaker AstraZeneca cut deaths in half among a subset of early-stage lung cancer patients who had undergone surgery, according to new clinical trial results.
Source: NBCNews - 🏆 10. / 86 Read more »
Lung cancer pill drastically cuts risk of death after surgeryTaking the drug Tagrisso daily after surgery reduced non-small cell lung cancer patients' death risk by more than 50%.
Source: LiveScience - 🏆 538. / 51 Read more »